An early phase I safety study of intravenous monoclonal anti-TNF antibodies in two patients with MS resulted in a transient increase in gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) and inflammatory abnormalities on cerebrospinal fluid (CSF) analysis (14). Here, TNF is linked to myeloid sarcoma.